Inova Heart and Vascular Institute, Falls Church, Virginia, USA; U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA.
JACC Heart Fail. 2022 Dec;10(12):889-901. doi: 10.1016/j.jchf.2022.09.012. Epub 2022 Nov 9.
The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory (HFC) and the Academic Research Consortium (ARC) composed of patients, academic investigators from the United States and Europe, the U.S. Food and Drug Administration, the National Institutes of Health, payers, and industry. Members discussed the measure, remote capture, and clinical utility of functional and quality-of-life endpoints for use in clinical trials of heart failure and cardiovascular therapeutics, with the goal of improving the efficiency of heart failure and cardiovascular clinical research, evidence generation, and thereby patient quality of life, functional status, and survival. Assessments of patient-reported outcomes and maximal and submaximal exercise tolerance are standardized and validated, but actigraphy remains inconsistent as a potential endpoint. This paper details those discussions and consensus recommendations.
心力衰竭学术研究联合会是心力衰竭协作组(HFC)与学术研究联合会(ARC)之间的合作伙伴关系,成员包括患者、来自美国和欧洲的学术研究人员、美国食品和药物管理局、美国国立卫生研究院、支付方和行业代表。成员们讨论了心力衰竭和心血管治疗药物临床试验中使用的功能和生活质量终点的衡量标准、远程采集和临床应用,目标是提高心力衰竭和心血管临床研究、证据生成的效率,从而改善患者的生活质量、功能状态和生存。患者报告结局和最大及次最大运动耐量的评估已经标准化和验证,但活动记录仪作为潜在终点仍然不一致。本文详细介绍了这些讨论和共识建议。